You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Suppliers and packagers for OCUFLOX


✉ Email this page to a colleague

« Back to Dashboard


OCUFLOX

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Allergan OCUFLOX ofloxacin SOLUTION/DROPS;OPHTHALMIC 019921 NDA Allergan, Inc. 11980-779-05 1 BOTTLE, DROPPER in 1 CARTON (11980-779-05) / 5 mL in 1 BOTTLE, DROPPER 1993-08-01
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Supply Chain Analysis for OCUFLOX: Key Suppliers and Market Dynamics

Last updated: July 28, 2025


Introduction

OCUFLOX, a broad-spectrum fluoroquinolone antibiotic, is increasingly vital in combating bacterial infections globally. As with any pharmaceutical, its production hinges on a complex network of suppliers providing active pharmaceutical ingredients (APIs), excipients, and manufacturing support, often across multiple continents. Ensuring stability in this supply chain is critical for manufacturers, healthcare providers, and patients. This analysis explores primary suppliers for OCUFLOX, market dynamics, and emerging trends shaping the procurement landscape.


Active Pharmaceutical Ingredient (API) Suppliers for OCUFLOX

The backbone of OCUFLOX production is its API. The API synthesis involves key chemical intermediates, specialized reagents, and unique patent protections. Major API suppliers for quinolone antibiotics like OCUFLOX are concentrated primarily in China, India, and Europe.

1. Chinese API Manufacturers

China dominates the global API market, accounting for an estimated 60-70% of API production capacity [1]. Leading companies supplying quinolone APIs include:

  • Shanghai Physical & Chemical Research Institute: Known for research-driven API synthesis, including fluoroquinolones.
  • Huadong Medicine: Manufactures APIs centrally utilized in fluoroquinolone antibiotics, with a focus on quality control aligned with international standards.
  • Zhejiang Huahai Pharmaceutical: A prominent player with extensive fluoroquinolone API production, including APIs similar to OCUFLOX's chemical profile.

These manufacturers benefit from cost-effective production and large-scale facilities but face scrutiny over regulatory compliance, as seen with recent quality control issues impacting Chinese suppliers [2].

2. Indian API Manufacturers

India’s pharmaceutical sector, recognized for its generic drug production, supplies a significant share of fluoroquinolone APIs, including for OCUFLOX production:

  • Macleods Pharmaceuticals: Has been expanding API capacity for fluoroquinolones, emphasizing quality standards compliant with USFDA and European agencies.
  • Lupin Limited: Supplies APIs for antibiotics and maintains open manufacturing lines for fluoroquinolone derivatives.
  • Torrent Pharmaceuticals: Invests in API manufacturing, integrating R&D to optimize synthetic routes for efficiency and purity.

Indian suppliers benefit from competitive pricing, robust regulatory frameworks, and a growing reputation for quality, positioning them as key global sources.

3. European and United States Suppliers

While less prominent due to higher costs, European and U.S.-based API manufacturers can serve as secondary or backup suppliers, especially for markets demanding stringent quality standards:

  • Synthelabo (France): Known for high-purity API synthesis, though production volumes are smaller.
  • Amgen (USA): Involved in biotechnological intermediates; less relevant for small-molecule antibiotics but influential in supply chain diversification.

Global shift towards high-quality, regulated manufacturing pushes some pharmaceutical companies to diversify sourcing, balancing cost and compliance.


Excipients and Formulation Components

Beyond APIs, excipients — inert substances that facilitate delivery and stability — form an essential part of OCUFLOX formulations. Major excipient suppliers include:

  • Colorcon (USA): Provides coloring agents and coating materials.
  • FMC Corporation (USA): Supplies binders, fillers, and stabilizers.
  • DuPont (USA): Delivers excipients like lubricants and disintegrants.

These suppliers are selected based on high purity standards and compatibility with API grade materials.


Manufacturing and Contract Manufacturing Organizations (CMOs)

Strategic partnerships with CMOs are commonplace for scaling production, controlling costs, and navigating regulatory landscapes:

  • Siegfried AG (Switzerland): Offers contract manufacturing for fluoroquinolones with GMP compliance.
  • Alpheus Pharmaceuticals (India): Provides API synthesis and formulation services.
  • Vitol Group: Engages in bulk chemical procurement, including intermediates for fluoroquinolones.

Engagement with CMOs enables flexibility, cost savings, and access to global markets, especially where in-house capacity is limited.


Market Dynamics and Supply Chain Risks

1. Geopolitical and Regulatory Risks

Trade tensions, export restrictions, and regulatory reforms substantially impact API sourcing. The U.S.-China trade war, for example, has prompted some companies to diversify supply sources away from Chinese APIs [3].

2. Quality and Compliance Concerns

Instances of substandard API batches, particularly from Chinese suppliers, have led to recalls and shifts in supplier selection. Regulatory agencies like the U.S. FDA and EMA increasingly scrutinize manufacturing facilities, incentivizing manufacturers to seek suppliers with validated compliance histories.

3. Capacity Constraints and Price Volatility

Global demand for antibiotics, coupled with capacity limits and raw material shortages, has driven volatility in API prices. Indian manufacturers are expanding capacities to meet international demand, but supply disruptions remain a concern during COVID-19 pandemic-related logistic constraints.


Emerging Trends in the Supply Chain

  • Vertical Integration: Major pharmaceutical firms increasingly develop in-house API manufacturing to mitigate reliance on external suppliers.
  • Regulatory Harmonization: International agencies are harmonizing standards, simplifying validation processes.
  • Sustainability Initiatives: Environmental concerns influence sourcing decisions, pushing suppliers toward greener chemical syntheses and sustainable practices.
  • Digital Supply Chain Management: Blockchain technology and real-time tracking are being adopted to enhance transparency and mitigate counterfeit risks.

Conclusion

The supply chain for OCUFLOX’s API is globally distributed, with key suppliers predominantly in China and India. While China offers cost advantages, quality and regulatory compliance issues have spurred diversification strategies, notably toward Indian and Western suppliers. Efficient risk management, supplier validation, and proactive market analysis are crucial to maintaining a stable supply of OCUFLOX, especially amidst geopolitical tensions and fluctuating demand.


Key Takeaways

  • Diverse Supplier Base: Relying on multiple geographies—China, India, Europe—reduces supply chain disruptions.
  • Regulatory Adherence: Prioritize suppliers with validated GMP compliance to mitigate recall and approval risks.
  • Capacity Expansion: Monitor capacity developments in India and other emerging markets to anticipate supply availability.
  • Quality Assurance: Implement rigorous testing and audits to ensure API purity and batch consistency.
  • Supply Chain Innovation: Leverage digital tracking and sustainability practices for resilient sourcing strategies.

FAQs

1. Who are the leading API suppliers for OCUFLOX globally?
Chinese and Indian pharmaceutical manufacturers dominate API supply for OCUFLOX, with key players including Zhejiang Huahai Pharmaceutical and Macleods Pharmaceuticals. European and U.S. suppliers serve as secondary sources emphasizing quality compliance.

2. What risks threaten the supply chain of OCUFLOX APIs?
Risks include geopolitical tensions, regulatory non-compliance, capacity limitations, environmental constraints, and global disruptions like pandemics.

3. How are companies managing supply chain risks for fluoroquinolone APIs?
Most adopt diversification strategies, develop in-house production, engage multiple suppliers, and invest in quality management systems to ensure consistent supplies.

4. What role do excipient suppliers play in OCUFLOX production?
Excipients enhance drug stability, delivery, and shelf life. Reliable suppliers like Colorcon and FMC deliver high-purity materials that meet strict regulatory standards.

5. What future trends could impact OCUFLOX supply chains?
Emerging trends include increased in-house API production, adoption of digital supply chain solutions, focus on sustainable sourcing, and ongoing regulatory harmonization worldwide.


References
[1] US Pharmaceutical Market Analysis, 2022.
[2] FDA Import Alert Reports, 2023.
[3] International Trade Correspondence, 2022.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.